An increase in protocol complexity is paving the way for machine learning models to optimize trial design.
Aleksa Jovanovic MD, PhD
Advertisement
Scientific Engagement and Innovation Specialist, Wemedoo AG
Articles by Aleksa Jovanovic MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
